Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 3,528 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: biospecimen Collection Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Oral Microbiome Sampling for BE

NCT05133102
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Sample collection
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Prospective Registry of Multiplex Testing (PROMPT)

NCT02665195
View directory record Official record
Conditions
Genetic Testing
Interventions
saliva specimen, questionnaire
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
10
States / cities
Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Completed No phase listed Observational

Exploring Outcomes and Characteristics of Myasthenia Gravis 2

NCT06002945
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Blood sample
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

NCT02837705
View directory record Official record
Conditions
Prion Diseases
Interventions
blood draw
Other
Lead sponsor
University of Zurich
Other
Eligibility
1 Year to 99 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Nov 11, 2026, 2:53 PM EST
Completed No phase listed Observational

Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression

NCT01531881
View directory record Official record
Conditions
Oral Cancer
Interventions
Not listed
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Nov 11, 2026, 2:53 PM EST
Completed Phase 1 Interventional

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

NCT00031681
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer, Gastrointestinal Stromal Tumor, HER2-negative Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Cell Lung Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Triple-negative Breast Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Nov 11, 2026, 2:53 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

NCT04231877
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Prednisone, Etoposide, Doxorubicin, Cyclophosphamide, Glofitamab, Multigated Acquisition Scan, Echocardiography Test, FDG-Positron Emission Tomography, Computed Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting Phase 1 Interventional

Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder

NCT07844694
View directory record Official record
Conditions
Familial Platelet Disorder With Associated Myeloid Malignancy
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Sirolimus
Procedure · Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01155375
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting Not applicable Interventional

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

NCT07468903
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

NCT02280161
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
cytology specimen collection procedure
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Prevention of Colorectal Cancer Through Multiomics Blood Testing

NCT04369053
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers
Interventions
Freenome test
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
45 Years to 85 Years
Enrollment
48,995 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 11, 2026, 2:53 PM EST
Terminated Phase 1 Interventional

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

NCT03121677
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Personalized tumor vaccine, Poly ICLC, Nivolumab, Peripheral blood draws, Leukapheresis, Rituximab, Biopsy
Biological · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

NCT07638007
View directory record Official record
Conditions
Disease/Condition Name Cancer-related Cognitive Dysfunction, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Not listed
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational

Large Algorithm Setting and Validation Study

NCT07607470
View directory record Official record
Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial
Interventions
Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP, Hologic Aptima® BV Assay, Yeast Culture
Diagnostic Test
Lead sponsor
Nanopath, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
North Miami, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational

Role of Gut Microbiome in Cancer Therapy

NCT05112614
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies

NCT03099850
View directory record Official record
Conditions
Pancreatitis
Interventions
Data Management and Monitoring
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

NCT02726750
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting No phase listed Observational

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

NCT06732414
View directory record Official record
Conditions
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Recruiting Phase 2 Interventional

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

NCT04941716
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies

NCT02217215
View directory record Official record
Conditions
Cervical Disease
Interventions
CNDS Advanced Cervical Scan
Device
Lead sponsor
Guided Therapeutics
Industry
Eligibility
21 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Nov 11, 2026, 2:53 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

Extracellular RNA Markers of Liver Disease and Cancer

NCT02908048
View directory record Official record
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
Interventions
Blood samples
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

NCT03604978
View directory record Official record
Conditions
Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions
Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 11, 2026, 2:53 PM EST
Completed Phase 4 Interventional

Prospective Clinicogenomic Program

NCT04180176
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions
Blood Draw
Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 11, 2026, 2:53 PM EST